- Home
- MYGN vs VIAV Comparison
MYGN vs VIAV Comparison
Compare MYGN & VIAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- VIAV
- Stock Information
- Founded
- MYGN 1991
- VIAV 1923
- Country
- MYGN United States
- VIAV United States
- Employees
- MYGN N/A
- VIAV N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VIAV Semiconductors
- Sector
- MYGN Health Care
- VIAV Technology
- Exchange
- MYGN Nasdaq
- VIAV Nasdaq
- Market Cap
- MYGN 2.0B
- VIAV 2.2B
- IPO Year
- MYGN 1995
- VIAV 1993
- Fundamental
- Price
- MYGN $12.39
- VIAV $10.22
- Analyst Decision
- MYGN Hold
- VIAV Hold
- Analyst Count
- MYGN 12
- VIAV 9
- Target Price
- MYGN $23.92
- VIAV $11.16
- AVG Volume (30 Days)
- MYGN 1.0M
- VIAV 1.3M
- Earning Date
- MYGN 02-25-2025
- VIAV 01-30-2025
- Dividend Yield
- MYGN N/A
- VIAV N/A
- EPS Growth
- MYGN N/A
- VIAV N/A
- EPS
- MYGN N/A
- VIAV N/A
- Revenue
- MYGN $823,600,000.00
- VIAV $990,700,000.00
- Revenue This Year
- MYGN $13.82
- VIAV $4.66
- Revenue Next Year
- MYGN $4.59
- VIAV $6.69
- P/E Ratio
- MYGN N/A
- VIAV N/A
- Revenue Growth
- MYGN 12.15
- VIAV N/A
- 52 Week Low
- MYGN $12.17
- VIAV $6.60
- 52 Week High
- MYGN $29.30
- VIAV $11.49
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- VIAV 51.54
- Support Level
- MYGN $12.17
- VIAV $10.03
- Resistance Level
- MYGN $15.08
- VIAV $10.35
- Average True Range (ATR)
- MYGN 0.79
- VIAV 0.22
- MACD
- MYGN -0.01
- VIAV -0.01
- Stochastic Oscillator
- MYGN 7.56
- VIAV 77.27
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About VIAV Viavi Solutions Inc.
Viavi Solutions Inc. is a global provider of network test, monitoring and assurance solutions to communications service providers, enterprises, network equipment manufacturers, civil government, military and avionics customers. The company also offers high-performance thin-film optical coatings, providing light management solutions to anti-counterfeiting, 3D sensing, electronics, automotive, defense and instrumentation markets. Its operating segments include Network Enablement, Service Enablement, and Optical Security and Performance Products. Geographically, it derives a majority of revenue from the United States.